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Abstract
The feasibility of using quantitative diffuse reflectance spectroscopy to longitudinally monitor physiological response
to cancer therapy was evaluated in a preclinical model. This study included two groups of nudemice bearing 4T1 flank
tumors (N = 50), half of which were treated with a maximum tolerated dose of doxorubicin (DOX). Diffuse reflectance
spectra were collected from tumors during a period of 2 weeks using a fiber-optic probe coupled to a spectrometer.
These spectra were quantified using an inverse scalable Monte Carlo model of light transport in tissue to extract
the concentrations of oxygenated, deoxygenated hemoglobin (dHb), and a wavelength mean reduced scattering co-
efficient (<μs′>). The tumor growth rates of the treated and control groups were nearly identical, as were changes
in the scattering parameter <μs′> during this time frame. However, tumors treated with DOX showed a transient
but significant increase in blood oxygen saturation. A comparison between the optically derived and immunohisto-
chemical end points in a subset of the 50 animals showed that the temporal kinetics of dHb concentration and <μs′>
were highly concordant with those of hypoxic and necrotic fractions, respectively. In conclusion, optical methods
could function as a “screening” technology in longitudinal studies of small animal tumor models to accelerate de-
velopment and testing of new anticancer drugs. This technique could isolate specific landmark time points at which
more expensive and sophisticated imaging methods or immunohistochemistry could be performed.
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Introduction
Preclinical animal models are widely used in studies seeking to under-
stand cancer biology, particularly, tumor growth, and metastatic behav-
ior [1]. Animal tumor models have provided a template for researchers
to understand the genetic basis of molecular pathways involved in
tumorigenesis, elucidate the detailed understanding of drug delivery
and transport in solid tumors, and investigate the effects of novel thera-
peutic regimens [2,3]. For decades, the standard method for evaluat-
ing the merits of new therapeutic agents in preclinical models has
been the standard tumor growth delay assay. This method quantifies
the growth rates of control and treated tumors to determine whether
a new therapeutic regimen provides any slowing of growth compared
with controls. Although this method has been valuable, it hides a pleth-
ora of pathologic and physiologic changes that occur in treated tumors
that could have important therapeutic implications. A case in point
involves “vascular targeting drugs,” such as combrestatin A4. These
compounds cause substantial damage to tumor microvasculature within
a few minutes of administration [4] and can lead to complete necrosis
of the central portions of a tumor within hours [5]. However, a standard
growth delay method exhibits no therapeutic advantage to giving these
drugs because the cells at the tumor–normal tissue boundary repopulate
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the tumor very rapidly, aided by a rapid influx of endothelial cell pro-
genitors that promote rapid recovery of angiogenesis [6]. Similarly, it has
been shown that inhibition of the hypoxia-inducible factor (HIF-1)
causes profound metabolic stress on hypoxic cells because HIF-1 is re-
sponsible for upregulating nearly all of the genes involved in anaerobic
metabolism [7]. Glucose is the only viable energy substrate for hypoxic
cells; thus, in the absence of HIF-1, these cells starve to death, leaving
only a small viable rim of tumor cells growing at the margin of the origi-
nal tumor. Yet, on using a standard growth delay method to evaluate
the effects ofHIF-1 inhibition, it has been shown that there was virtually
no effect on growth delay because growth at the tumor margin hid
the underlying changes in tissue physiology and pathology [7]. It is
therefore important to assess the underlying tumor physiological and
pathologic changes to improve treatment efficacy.
One such important parameter that influences tumor growth, me-
tabolism, treatment resistance, and metastatic behavior is tumor hypoxia
or low oxygen tension [8,9]. Tissue hypoxia is definitively diagnosed
using immunohistochemical assays that directly detect intrinsic markers
of hypoxia (such as carbonic anhydrase IX, osteopontin, or HIF-1) or
relies on the use of extrinsic agents (such as pimonidazole or EF5) to se-
lectively stain hypoxic cells [10]. A standard nonhistologic method to
measure hypoxia is electrode polarography; this yields point measure-
ments of PO2 (sampled from ∼100 to 300 cells) at spatial locations along
the path of electrode insertion andwithdrawal within the tissue [11]. Tis-
sue oxygen concentrations have also been assessed using perfluorinated
compounds in combination with electron paramagnetic resonance
spectroscopy, indirectly using 2-nitroimidazoles with positron emission
tomography (PET) and magnetic resonance (MR) spectroscopy [10].
Another parameter used to assess the efficacy of cancer therapies in-
volves alterations in tumor morphology and structure including cellular
and nuclear features of shape, size, crowding, chromatin organization,
and DNA structure [12]. This is most commonly done using histo-
pathologic and immunohistochemistry (IHC) techniques. These meth-
ods identify two important features of cell death, namely, apoptosis and
necrosis, both of which have the ability to predict disease-free survival
in patients after therapy [13–15]. Alternately, PET and MR imaging
(MRI) have been applied to noninvasively detect cell death in vivo.
MRI measures of the apparent diffusion coefficient of water in tissue
can provide information regarding tissue structure from the water con-
tent present in the intracellular and the extracellular space, which in
turn can be used to assess cell death occurring through necrosis or apop-
tosis [16,17]. Conversely, PET imaging methods for sensing apoptosis
and/or necrosis rely on using labeled apoptosis or necrosis markers such
as 18F-labeled annexin V [17].
Studies seeking to quantify changes in physiology including tumor
hypoxia and/or cell death using IHC face logistical challenges because
thesemethods require killing animals at regularly spaced intervals to assay
them. Moreover, longitudinal studies involving IHC cannot repeatedly
track individual subjects because the measurement of an individual
using IHC techniques necessitates the loss of the subject. Both these con-
straints lead to the requirement of large sample sizes to draw meaningful
conclusions about a particular therapy. Alternate high-resolution, sophis-
ticated, and noninvasive imaging techniques such as MRI or PET can
repeatedly obtain serial measurements on individual subjects, but they
have high associated operating costs and may not always be amenable
to frequent use in small animal studies.
Here, we present an optical spectroscopic approach to nondestruc-
tively and dynamically quantify changes in several key biomarkers of
carcinogenesis, specifically, tumor oxygenation and cellular morphology
(necrosis, in particular) in preclinical tumor models. Our technology
is based on diffuse reflectance spectroscopy that quantifies the wave-
length dependence of the reflected light after it has undergone absorp-
tion and scattering interactions in the tissue [18–20]. Primary absorbers
in soft tissues include oxygenated hemoglobin (HbO2) and deoxygen-
ated hemoglobin (dHb), both of which indicate blood oxygenation
status of the tissue. Tissue scattering contains information about the
underlying cellular architecture, is sensitive to the size and density of
cellular and subcellular structures such as nuclei and mitochondria,
and can be altered by cell death and/or cell proliferation. The sensing
depth offered by diffuse reflectance spectroscopy depends on factors
that include the source-detector geometry used to deliver and collect
the light and the optical properties (absorption and scattering) of the
interrogated tissue. Because both the optical absorption and scattering
of most tissues decrease with increasing wavelength, the penetration
depth of light increases from a few millimeters in the UV-visible spec-
trum to several centimeters in the near-infrared (NIR). Our technology
is designed to be used in the visible spectral range, which provides a
sensing depth in the millimeter range and is comparable to the size
of tumors in preclinical models such as nude mice. Traditionally, quan-
titative extraction of absorber concentrations (which yield information
on the blood oxygen status and total blood concentration) and tissue
scattering are typically obtained using closed-form analytical expres-
sions of light transport in turbid medium, which are best suited for
use in the longer, NIR spectral range [21]. We have developed a series
of computational Monte Carlo (MC) algorithms that can quantitatively
extract tissue absorption and scattering in vivo [22] while accurately
accounting for the fiber probe geometry over a wide wavelength range
including the visible and NIR. Unlike the closed-form analytical ex-
pressions, these computational models are well suited to the visible spec-
tral regime and for small source-detector separations as is proposed for
use on tumors in small animal models.
This article focuses on the use of visible diffuse reflectance spectros-
copy in characterizing changes in optical parameters related to tumor
hypoxia and necrosis in vivo in a preclinical model of breast cancer.
4T1 breast tumors were grown in the flank of nude mice, and the ani-
mals were separated into control and treatment groups and monitored
optically during a 2-week period. The treated animals received a maxi-
mum tolerated dose (MTD) of doxorubicin (DOX). These diffuse reflec-
tance spectra were then processed through a quantitative MC model
developed by our group [22] to extract the concentrations of HbO2
and dHb in blood within the tumor vasculature along with an associated
reduced scattering coefficient spectrum. Tumors from animals in both
groups were also resected at four time points for IHC analysis of hypoxic
and necrotic fractions. The main findings from our study were as fol-
lows: Treatment withMTDDOX showed no differences in the standard
growth delays between the treated and untreated tumors. However,
tumors treated with DOX showed a transient but significant increase
in blood oxygen saturation, which is consistent with previously published
studies [23]. A comparison between the optically derived and IHC end
points showed that the temporal kinetics of dHb concentration and the
reduced scattering coefficient were highly concordant with those of
hypoxic and necrotic fractions, respectively.
Materials and Methods
Animal Study Protocol
Fifty nude mice with a mean ± SD weight of 20.7 ± 3.2 g were or-
dered from the National Cancer Institute (Bethesda, MD) and stored at
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the Duke animal facility in a 12-hour dark-light cycle. Food and water
were allowed ad libitum. Approximately, 106 4T1 mouse breast carci-
noma cells suspended in 0.1 ml of serum-free medium were inocu-
lated subcutaneously in the right flank of the animals. Once the
tumor diameter reached 4 to 6 mm, the animals were evenly distributed
(by tumor size) into control and treatment groups (each group had
25 animals). The treatment group received an MTD dose of DOX
(10 mg/kg, intravenously using a previously prepared solution of
2-mg/ml DOX), whereas the control group received an equivalent vol-
ume of saline. These studies were approved by the Duke Institutional
Laboratory Animal Care and Use Committee.
The tumors were monitored optically before treatment to get base-
line measurements (day 0) and then on days 2, 5, 7, 10, and 13 after
DOX or saline administration. The animals were maintained under
anesthesia by isoflurane breathing (1.5% isoflurane gas mixed with
oxygen) throughout the course of the optical measurements. Five ran-
domly chosen animals, from each group, were removed for IHC on
days 0, 5, 10, and 13. These treatment schedules and time points were
selected from previous pilot studies that showed maximal differences
in the optical end points between the treated and the control groups.
The tumors from the animals designated for IHC were resected, snap-
frozen by placing the tumor in a container immersed in liquid nitrogen,
and stored for subsequent histologic diagnosis and IHC. For each of
these animals, the outline of the fiber-optic probe was traced on the
surface of the tumor immediately after the optical measurement to en-
sure that the resected tumors could be sectioned as closely parallel to the
face of the fiber-optic probe as possible, thereby yielding sections from
nearly the same tissue volumes as sensed by the optical measurements.
Immunohistochemistry
The harvested, snap-frozen tumors were sliced into 10-μm-thick sec-
tions using a cryotome (CM1850; Leica, Inc., Nussloch, Germany).
The orientation of the resected tumor on the microtome before section-
ing was determined from the marked circle on the tumor surface that
indicated the outline of fiber-optic probe position such that the sections
were parallel to the face of the optical probe. For each tumor, five sec-
tions were obtained from depths of 600 μm and 1.6 mm below the
surface. Slides were counted from the start of cutting and were num-
bered consecutively so that the depth of each section from the surface
could be computed.
The hypoxic fraction for each section was determined using pimoni-
dazole and the necrotic fractions were assessed using hematoxylin and
eosin (H&E) staining. Pimonidazole as the hypoxia marker was immu-
nostained using a direct labeling protocol: pimonidazole was injected in-
traperitoneally (at a dose of 60 mg/kg, from a solution of 10-mg/ml
pimonidazole) 30 minutes before the animals were killed. The resected
tumor sections were fixed in cold acetone for 15 minutes and blocked in
donkey serum blocking reagent. The primary antibody to pimonidazole
(Hypoxyprobe-1 kits; NPI, Inc, Burlington, MA) was labeled with a
fluorescent immunoglobulin G probe (no. Z25005; Molecular Probes,
Eugene, OR) and then incubated with tumor sections for 1 hour at room
temperature, washedwith phosphate-buffered saline, and fixed with 10%
buffered formalin for 1 minute. Stained tumor sections were kept in 1%
formaldehyde phosphate-buffered saline and imaged within 3 to 4 days.
After imaging, the sections were stained with H&E to allow visualization
of histologic structure and quantify necrotic fraction.
Quantification of Hypoxic and Necrotic Fractions
The hypoxic fraction was determined using pimonidazole-stained
images. Theoretically, pimonidazole staining is substantially increased
when the intracellular oxygen tension falls to less than 10 mmHg [24].
A higher intensity level of the fluorescence staining indicated higher
hypoxia in the tissue. Imaged areas whose intensity levels were higher
than a given fixed threshold were marked hypoxic, and the hypoxic
fraction was calculated as a percentage area of vital tissue with the
necrotic areas excluded. Because each resected mass had sections from
depths of 600 μm and 1.6 mm, the hypoxic fraction for the tumor was
the averaged value from both sections.
The necrotic fractions were quantified using H&E-stained sections.
The necrotic areas were characterized by higher eosin staining, dark and
condensed nuclei debris, and incomplete cell shapes. The necrotic frac-
tion was calculated as the ratio of the necrotic area to the overall tissue
area across each section. As before, because there were two sections
corresponding to two different depths for each tumor, the averaged
values were considered as the necrotic fraction for a given tumor.
Diffuse Reflectance Spectroscopy
A fiber-optic–based spectrometer (SkinSkan; JY Horiba, Edison, NJ)
was used to measure diffuse reflectance spectra from the tumors. This
instrument used a 150-W xenon lamp as the source, its light was fil-
tered through a double-grating excitation monochromator for delivery,
and an emission monochromator was coupled to a photomultiplier
tube for light detection. The illumination and collection of the light
to tissue were achieved through a bifurcated fiber-optic probe (Fig-
ure 1B), consisting of a central collection core of 29 fibers (arranged
circularly within a diameter of 1.52 mm) surrounded by 30 illumina-
tion fibers (arranged nearly concentric to the central core with an outer
diameter of 2.18 mm), where each individual fiber was 200 μm in
diameter [22]. Diffuse reflectance spectra were measured between
350 and 600 nm by gently pushing the probe to make contact with
the tumor surface and held fixed by a clamp throughout the course
of the optical measurements. The diffuse reflectance at each wavelength
was collected by integrating the signal on the photomultiplier tube
for 0.1 second. The acquired spectra were calibrated by dividing the
tissue diffuse reflectance spectrum by the diffuse reflectance spectrum
obtained from a 99% reflectance Spectralon standard (SRS-99-020;
Labsphere, Inc, North Sutton, NH) to account for variations in system
throughput and wavelength response of the instrument.
Extraction of HbO2, dHb, and μs′
Two measurements of diffuse optical reflectance spectra were col-
lected from each animal on each measurement day, consecutively.
These reflectance spectra were analyzed using the inverse MC model
developed by our group [22] to extract wavelength-dependent absorp-
tion and scattering coefficient spectra; here, the tissue absorption/
scattering coefficient is defined as the inverse mean free path for a
photon (of given wavelength) to undergo an absorption/scattering
event during propagation in the tissue. The tissue absorption coefficient
was assumed to have contributions fromHbO2, dHb, and skin (extinc-
tion coefficients for these absorbers were obtained from a previously
tabulated database [25]), whereas the scattering coefficient was cal-
culated using a Mie theory model for spherical scatterers [22]. The fol-
lowing parameters were derived from the absorption and scattering
coefficient spectra extracted using the inverseMCmodel: concentration
of HbO2, concentration of dHb, a skin-related absorption factor [26],
and the reduced scattering spectrum, which, when averaged, gave a
wavelength mean reduced scattering coefficient <μs′> [22]. The mean
value of each parameter was computed from the two sets of measured
diffuse reflectance spectra, for each animal, on each measurement day.
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The extracted HbO2 and dHb concentrations were used to compute
two additional tissue physiological parameters: the total hemoglobin
concentration, [THb] = [HbO2] + [dHb]; and the oxygen saturation,
SO2 = 100 × [HbO2] / [THb]. The wavelength range used for data
analysis was 480 to 600 nm. This range was selected based on some
systematic modeling studies described in the next paragraphs.
The inverse MCmodel [22] assumes that the interrogated tissue is an
optically homogeneous, semi-infinite, turbid medium. However, the
experimental measurements are better represented by a two-layered tis-
sue model with a layer of skin covering the underlying tumor, as shown
schematically in Figure 1A. To ascertain that we were sensitive to the un-
derlying tumor physiology without being confounded by the presence
Figure 1. The tissue models, fiber probe schematic, the absorption and scattering coefficients of skin and tumor used in the modeling
studies, and the predicted diffuse reflectance spectra. (A) Tissue geometries with and without a skin layer (0.3 mm). (B) Schematic of
the composite probe used in these simulations and experiments. (C) Absorption coefficient spectra for the tumor (red crosses) and skin
layers (blue crosses). (D) Scattering coefficient spectra for the tumor (red squares) and skin layers (blue squares). (E) Simulated diffuse
reflectance spectra for the single-layer model (blue crosses) and the two-layered model (red triangles).
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of the skin layer, we conducted a series of simulations using standard
forward MC simulations [27] for two cases: 1) for a semi-infinite homo-
geneous tissue model (representing the tumor) and 2) for a two-layered
tissue model that included a 300-μm-thick layer of skin atop the semi-
infinite tumor, as shown in Figure 1A. These simulations allowed us to
estimate perturbations in the diffuse reflectance spectra due to the pres-
ence of the skin layer. The skin layer thickness was set to 300 μm in these
simulations because the mean ± SD skin thickness in five animals bear-
ing 4T1 tumors was histologicallymeasured to be 290 ± 60 μm. Forward
MC simulations were computed for the two tissue models mentioned
previously to generate the diffuse reflectance spectrum between 350
and 600 nm at intervals of 10 nm to simulate experimental measure-
ments. It is to be noted that these simulations considered the exact fiber
probe geometry shown in Figure 1B for calculations following the pro-
cedure outlined previously [22]. Figure 1,C andD, shows representative
wavelength-dependent optical absorption and scattering coefficients of
each layer, respectively, used in these simulations. The optical properties
(absorption and scattering coefficients) of mouse skin were obtained
from previously tabulated data [28], whereas those of the tumor were
obtained from the results of an inversion procedure from a randomly
selected animal in this study. These modeling studies considered the
exact geometries of the source-detector fiber pairs of the composite
fiber-optic probe to accurately compute the diffuse reflectance for the
tissue model, as described elsewhere [22]. Figure 1E shows the simu-
lated diffuse reflectance data for the single-layer (blue crosses) and the
two-layered tissue models (red triangles). The presence of the skin layer
strongly perturbed the measured diffuse reflectance spectra for wave-
lengths below 450 nm, whereas for wavelengths above 480 nm, the dif-
fuse reflectance spectra for both models were quite similar. We therefore
estimated that the effect of the skin layer on the measured diffuse reflec-
tance was small in the spectral region between 480 and 600 nm and thus
used the diffuse reflectance spanning 480 to 600 nm for all extractions of
the absorption and scattering coefficients of the tissue.
Statistical Methods
To examine the profiles of optical parameters over time, a longitu-
dinal mixed-effects model was applied to these end points as a common
method for analyzing repeated-measures data from mouse xenografts
models [29,30]. A log transformation was required to stabilize the vari-
ance and obtain residuals that were normally distributed for the optical
estimates of [dHb], [THb], and <μs′> (data not shown). The covari-
ance structure was estimated using a compound symmetric model that
was determined to be optimal by the Bayesian information criteria.
The significance of fixed effects (i.e., treatment [Controls vsDOX], time
point [day], and their interactions) was determined in a step-up fashion
using likelihood ratio tests undermaximum likelihood estimation. Analy-
ses were performed using R version 2.8.1 (www.r-project.org). For all
tests, statistical significance was set at P < .05.
Results
Intratumor versus Intertumor Variability in the Extracted
Optical End Points
To assess variations in each of the extracted optical end points within
each animal due to spatial sampling of the tumor relative to the varia-
tion in these end points across tumors in different animals, diffuse re-
flectance spectra were obtained from five different spatial locations on
the tumor for each animal of a total of four randomly selected animals
(two treated and two control animals) on day 14. The mean coefficients
of variation for the optical parameters (calculated using the five mea-
surements per animal) within an animal were compared with the co-
efficient of variation computed for the 10 remaining animals on day 14
(the other 40 animals were previously killed for IHC). These data are
tabulated in Table 1 and show that the interanimal coefficient of varia-
tion was significantly greater than intra-animal values for all extracted
optical parameters.
Representative Optical Absorption and Scattering Spectra
Figure 2 shows the diffuse reflectance spectra, the extracted absorp-
tion, and reduced scattering spectra for two representative animals (one
treated and one control animal) on each measurement day until day 10.
Figure 2, A and B, shows the measured diffuse reflectance spectra
(symbols) and the corresponding MC model fits (lines) for one repre-
sentative treated animal (Figure 2A, blue symbols) and one control ani-
mal (Figure 2B, red symbols). As seen in these figures, the model fit the
measured data well (with mean residual errors <3%). Figure 2, C and
D, shows the extracted absorption coefficient spectra for the treated
(blue symbols) and control animals (red symbols), whereas Figure 2, E
and F, shows the reduced scattering coefficient spectra for these ani-
mals, respectively. The absorption spectra on day 0 for both animals
indicate that the tumors in both animals were poorly oxygenated at
baseline because it is well known that the absorption coefficient (be-
tween 480 and 600 nm) of dHb exhibits a single peak at 550 nm,
whereas the absorption coefficient of HbO2 contains two absorption
bands (called the α and β bands with peaks at 575 and 540 nm, re-
spectively). By day 5, the tumor in the treated animal became pro-
gressively more oxygenated with time as seen by the growth of the
characteristic α/β bands of HbO2, whereas the tumor in the control
animal continued to show a prominent single absorption band of
dHb. However, the THb (which is proportional to the magnitude of
the absorption coefficient) clearly increased in both animals with time.
The overall shapes in the scattering coefficients for either animal are
featureless, relative to the absorption spectra, but both animals showed
general increases in mean scattering values with time.
Longitudinal Trends in the Optical and Tumor Volume
End points
Figure 3 shows the temporal kinetics of the concentration of HbO2
(Figure 3A), concentration of dHb (Figure 3B), the oxygen saturation
(SO2; Figure 3C), the THb concentration (Figure 3D), the mean re-
duced scattering coefficient (<μs′>; Figure 3E), and the tumor volumes
(Figure 3F) extracted from the data shown in Figure 2 for both animals.
The blue asterisks show the data for the treated animal, the red circles
show the control animal, whereas the error bars correspond to the
SD between the two successive reflectance scans obtained from each
animal at each time point. These data more clearly isolate the changes
observed in Figure 2.
Figure 4 shows these longitudinal variations, for each optical end
point (Figure 4, A–E) and tumor volume, across all treated animals (blue
Table 1. Intertumor versus Intratumor Coefficient of Variation in the Extracted Optical End Points.
Optical End Point HbO2 dHb <μs′>
Mean coefficient of variance within animal (n = 4) 0.26 (0.04) 0.21 (0.11) 0.12 (0.04)
Coefficient of variance across animals (n = 10) 0.62 0.67 0.21
Values in parenthesis indicate the SD in the coefficient of variance (computed across the four animals).
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bars) and across all control animals (red bars). The numbers above the
bars in Figure 4A represent the total number of animals that were eval-
uated for each group at that time point. A regression line fitted to all avail-
able longitudinal data for each end point across time per group is also
shown in Figure 4 (blue lines indicate trends for treated animals; red lines,
trends for controls). Figure 4A shows that treatment with DOX increases
the mean concentration of HbO2 across time within the tumors of the
treated group relative to the animals in the control group. A similar in-
crease in the mean SO2 values was observed in the treated tumors rela-
tive to that in the control group (Figure 4C). Treatment with DOX also
caused the treated tumors to have decreased dHb over time (Figure 4B)
relative to the control group. The regression lines in Figure 4, D and E ,
indicate that the both [THb] content as well as <μs′> changed nearly
identically across time in both the treated and the control groups. Fig-
ure 4F shows similar rates of tumor growth for both groups.
To examine whether any of the optical end points showed an effect
specifically due to treatment, a longitudinal mixed-effects model was ap-
plied to the repeated measures of all end points. These analyses indicated
Figure 2. The measured (symbols) and fitted (lines) diffuse reflectance spectra for a representative treated (A, blue symbols) and control
(B, red symbols) animal during the first 5 days. Data are shown up to day 10 because these animals were killed for IHC on day 10 (see
text). Extracted absorption (C and D) and reduced scattering coefficient spectra (E and F) for the treated (blue symbols, C and E) and the
control (red symbols, D and F) animals.
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that that the plotted linear trends were significantly different between
the treated and the control groups for two of the six variables: treatment
with DOX showed significant increases in [HbO2] (P = .01) and im-
proved tumor SO2 (P < .001) in the treated tumors, relative to the
tumors in the control group. The trends for [dHb] showed that the
treated group had lower dHb levels relative to the controls, but they were
not statistically significant (P = .25).
Immunohistochemical Staining
Figure 5 shows a panel of representative images from six tumor sec-
tions that were stained using Hoechst and pimonidazole. The sections
shown were obtained from three different animals at each of the three
different time points (columns from left to right show data on days 0,
5, and 10) for each of the two groups (top and bottom rows show data
for control and treated animals, respectively). The animals shown on
Figure 3. Temporal kinetics of [HbO2] (A), [dHb] (B), SO2 (C), [THb] (D), <μs′> (E), and tumor volumes (F) for the same animals shown in
Figure 2. The blue asterisks show the data for the treated animal and the red circles show the control animal. The symbols represent the
mean value obtained from the spectra obtained from two consecutive scans of the diffuse reflectance. Error bars indicate SD.
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day 10 here correspond to the treated and control animals whose op-
tical data were shown in Figures 2 and 3. Blue marks Hoechst-33342
fluorescence (indicating perfused areas within the sections), whereas
orange-stained areas show pimonidazole antibody binding (marking
the hypoxic tissue area). The dark regions in these figures were classified
either as necrotic (using corresponding H&E-stained sections; data not
shown) or as nonperfused viable tissue. These data indicate that the
hypoxic fraction for the control group was higher on day 10 compared
with day 0, whereas these trends were reversed in case of the treated
animals in these representative set of images.
Concordance between Optical and IHC End Points
The time course of changes in the IHC end points, hypoxic and ne-
crotic fractions, were compared against the time course of changes in the
most closely associated optical end point and are shown in Figure 6.
Similar trends were observed between hypoxic fraction and dHb con-
centration (Figure 6, A and B) and between the necrotic fraction and
<μs′> (Figure 6, C and D) for animals from either group. It should be
noted that the optical end points shown here were obtained using only
five mice per group that underwent IHC at each time point and thus
do not include the full sample size shown in Figure 4. To quantitatively
Figure 4. Longitudinal variations in all end points for each group across time: [HbO2] (A), [dHb] (B), SO2 (C), [THb] (D), <μs′> (E), and
tumor volume (F). Bars indicate mean values for each end point computed across all available animals (shown above each data bar for
each day in panel A), at each particular time point, per group. Vertical lines on each bar are SEs. The dashed lines are lines of regression
computed over all optical measurements across time using all available animals (at that time point) in each group (blue line indicates
treated data; red line, control data).
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assess that the trends displayed by the optical and IHC end points are
similar across time, multivariate statistical models were built in an addi-
tive fashion to determine the effect of time (day) and treatment for both
groups of data. These analyses indicated that the hypoxic fractions and
dHb concentrations required the addition of quadratic polynomial terms
(P < .001) to fit the temporal variations of the data, whereas the necrotic
fractions and the <μs′> required cubic-order polynomial (P < .001) terms
to capture temporal variations in these parameters across time. How-
ever, neither the hypoxic fraction nor the necrotic fraction (or their
optical analogues) showed statistically significant differences in the tem-
poral trends between the treated and the control groups. A summary of
the conclusions of the multivariate statistical models is as follows: the
temporal trends between the hypoxic fractions and dHb concentrations
and between the necrotic fractions and the <μs′> were statistically similar,
but no effect of treatment was perceived across any of these parameters
in this smaller cohort of animals that was observed in the larger cohort
(Figure 4).
Given the linear increase with time in <μs′> and tumor volumes
seen in Figure 4, E and F, and the similarity of temporal trends in
<μs′> and necrotic fractions seen in Figure 6, C and D, we evaluated
the relationship between <μs′> with both necrotic fraction and tumor
volume in the treated and control animals through two-dimensional
scatter plots. Figure 7 shows the relationship between the estimated
<μs′> and necrotic fraction for the treated animals (Figure 7A, blue
symbols) and control animals (Figure 7B, red symbols). It should be
noted that the data in these figures are obtained only from the ani-
mals that underwent IHC. Figure 7, C and D, shows the dependence
of <μs′> on the tumor volume for all treated and control animals, re-
spectively. The dashed lines in each of these figures are the lines of re-
gression and show that the extracted <μs′> was related linearly related to
both the necrotic fraction and tumor volume in both the treated and
Figure 6. Comparisons between the optical and IHC end points. (A and B) Changes in mean hypoxic fractions assessed using IHC (plain
bars, left y-axis) and corresponding optical dHb measurements (hatched bars, right y-axis) for the treated (light blue, A) and control (light
red, B) animals. (C) Changes in histologically assessed necrotic fraction (plain bars, left y-axis) and optically determined <μs′> (hatched
bars, right y-axis) for the treated group (dark blue). (D) The same data for the control group (dark red). The optical data shown here were
obtained from the same animals used for IHC (five per group) per time point. Error bars indicate SEs.
Figure 5. Images of the tumor sections from six representative ani-
mals and time points stained using Hoechst and pimonidazole. Blue
marks Hoechst-33342 fluorescence, whereas the orange-stained
areas indicate pimonidazole binding. The percent hypoxic fractions
on days 0, 5, and 10 were 5%, 33%, and 41%, respectively, for the
control tumors and 22%, 49%, and 11%, respectively, for the treated
tumors. The dark regions were either necrotic or nonperfused, and
the percent necrotic fractions were assessed using H&E stains (data
not shown). Scale bar, 500 μm.
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the control groups, although these relationships were marginally stronger
in the control animals.
Discussion
Scientific investigators have recognized the need for being able to
noninvasively and repeatedly interrogate the underlying physiology
and pathology of tumors de novo and in response to therapy. This
recognition, in large part, has stimulated the revolution in molecular
and functional imaging in small animals using micro–computed tomog-
raphy, micro-PET, high-resolution MR, and ultrasound. Whereas all
of these methods can yield important information about the tumor,
they are very expensive and time-consuming and may require the use
ofmultiplemodalities to capture the full spectrumof relevant biomarkers.
Optical techniques are well suited to dynamically and repeatedly monitor
physiological and morphologic changes in small animal tumor models.
One could easily obtain simple yet quantitative spectroscopic end points
along with tumor dimensions and body weight, and these measurements
can then be used in the final analysis of treatment results to drive the
selection and timing for further detailed studies using micro–computed
tomography, MRI, or IHC, for example.
In this study, wemeasured changes in tumor physiology andmorphol-
ogy optically across a period of 2 weeks in a nude mouse model bearing
4T1 tumor treated with MTD DOX. The optical end points showed
that theHbO2 concentration and tumor SO2 in the treated animals were
statistically significantly increased after drug administration relative to the
untreated controls. Furthermore, there was an overall decrease in the
mean first-order temporal trend for dHb concentration in the treated
group, whereas it was increased for the animals in the control group
(although these differences were not statistically significant). Over-
all changes in THb and <μs′> were nearly identical for both control
and treated animals, similar to the trends observed in measured gross
tumor volumes.
Previously reported results are consistent with the optically based
findings in this study. Oxygenation measurements of untreated 4T1
tumors using hyperspectral imaging in a mouse window chamber
model have previously shown that these tumors became progressively
hypoxic over time [31] as was observed in our study. It has also been
shown that tumor cells treated with 10 mg/kg DOX in mice bearing
16/C mammary tumors showed improved oxygenation as soon as
4 hours after treatment [23]. Another study assessed changes in tumor
hypoxia in rats bearing 9L gliosarcoma tumors using a PO2 electrode
24 hours after administration of DOX treatment and reported that
the treatment improved the overall median PO2 to 5.2 mm Hg relative
to a pretreatment median PO2 value of 1.4 mm Hg [32]. It has also
been reported that untreated 4T1 tumors in BALB/c mice showed large
areas of necrosis in the central tumor core 2 to 4 weeks after tumor cell
implantation [33] and that MTD DOX (6.25 mg/kg) administration
to rats bearing MTLn3 mammary adenocarcinomas caused more than
75% of the area of tumor sections to become necrotic 48 hours after
treatment [34]. Observations of increased angiogenesis within un-
treated 4T1 tumor models in mice have been reported previously
[35]. However, there are conflicting reports on the antiangiogenic po-
tential of DOX in the literature. Most administrations of DOXuse low-
dose metronomic schedules, and this dosing routine has been shown to
increase angiogenesis in mesenteric tissue of adult male rats [36,37],
Figure 7. Relationships between the extracted <μs′> with necrotic fraction (A and B) and tumor volume (C and D) for the treated (blue
symbols/lines) and control animals (red symbols/lines). The dashed lines indicate the line of regression between the variables on each
plot, whereas the P value and the regression coefficient are shown on each plot. Different symbols represent data obtained on different
days and are shown in the figure legend.
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whereas another report that detected blood flow and perfusion in mice
implanted with the murine squamous cell carcinoma SCCVII observed
clear decreases in both blood flow and perfusion in the tumors after
administration of DOX [38].
IHC estimates of tumor hypoxia and necrosis that were quantified
longitudinally for animals in both groups showed that there were
transient increases in tumor hypoxia and necrosis through time for
both groups. Given the limited number of animals that were used to
obtain these IHC estimates, there were no statistical differences in
rates of change in either of these parameters with treatment. How-
ever, we were able to show here that there were optical end points
that statistically significantly tracked the polynomial time-dependent
trends observed in the quantified IHC end points for the correspond-
ing animals. Pairwise comparisons of the extracted <μs′> with necrotic
fraction and tumor volume across all animals indicated that there was
an increase in tissue scattering with both necrotic fraction and tumor
volume. Several factors have been suggested to contribute to an in-
crease or to a decrease in optical scattering in tissue [39]. These include
structural changes in the extracellular matrix of the tumor (breakdown
of collagen matrix, for instance [40]), changes in water content of tu-
mors (edema) [41], increased mitochondrial differentiation [42], nu-
clear size and shape, and cell density [43]. Alterations in tumor
volume can be affected by cell proliferation and/or cell death (apoptosis,
necrosis) and changes in the extracellular matrix density, thus changes
in tumor volume or viability can potentially impact tissue optical scat-
tering. Data in Figure 7 suggest that there were alterations in the cel-
lular architecture/density and/or the extracellular matrix with necrosis
that influenced tissue scattering. However, the exact basis for these
correlations (i.e., which morphologic constituents primarily contribute
to these correlations) is unknown at this time and will be the subject
of future exploratory studies. These data suggest that it may be pos-
sible to track tissue necrotic fraction in situ using the optical end point
of <μs′>.
This study shows that reflectance spectroscopy has the potential to
dynamically monitor changes in tumor physiology and morphology in
preclinical models and can therefore be used as a tool for longitudinal
drug screening studies, for instance, to perhaps determine important
time points at which there are maximal differences in tumor physio-
logical end points between animals receiving different treatments,
which might or might not be captured accurately through standard
tumor growth assays. This was clearly demonstrated by our study:
the optical measurements showed that treatment with DOX increased
tumor oxygenation, which was consistent with previously reported
studies. However, tumor volume measurements showed no effect of
the drug on controlling the rate of tumor growth. These low-cost,
fast optical techniques, in particular, diffuse reflectance spectroscopy,
could serve as ideal screening techniques that could shed light about
early changes in tumor physiology and morphology with treatments
and could provide significant additional insights along with standard
growth delay studies. These methods could also reduce the need for large
animal numbers in longitudinal studies investigating novel drugs and
therapeutics by serving as a guide that could provide specific landmark
time points for histologic and/or more sophisticated interventions.
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